PE20051089A1 - PYRAZOLE [1,5-A] PYRIMIDIN-7-IL-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS - Google Patents
PYRAZOLE [1,5-A] PYRIMIDIN-7-IL-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORSInfo
- Publication number
- PE20051089A1 PE20051089A1 PE2005000080A PE2005000080A PE20051089A1 PE 20051089 A1 PE20051089 A1 PE 20051089A1 PE 2005000080 A PE2005000080 A PE 2005000080A PE 2005000080 A PE2005000080 A PE 2005000080A PE 20051089 A1 PE20051089 A1 PE 20051089A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- pyrimidin
- piperazin
- methyl
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRAZOLO [1,5-a] PIRIMIDIN-7-IL-AMINA DE FORMULA (I), EN DONDE R1 ES H, HALOGENO O ALQUILO INFERIOR; R2 ES H, ARILO, HETEROARILO, ALQUILO INFERIOR, CICLOALQUILO, BENCILO, BENZOTIENILO, INDOLILO ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS; R3 ES H, ALQUILO INFERIOR, OPCIONALMENTE SUSTITUIDOS; A ES H, HALOGENO, BENZOTIENILO, PIRIDILO, FENILO, PIPERAZINILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: 3-{7-AMINO-3-[4-(4-METIL-PIPERAZIN-1-IL)-FENIL]-PIRAZOLO-[1,5-A]-PIPRIMIDIN-6-IL}-FENOL, 6-(3-BENCILOXI-FENIL)-3-[4-(4-METIL-PIPERAZIN-1-IL)-FENIL]-PIRAZOLO[1,5-A]PIRIMIDIN-7-IL)-FENOL, 6-(3-METOXI-FENIL)-4-[4-(4-METIL-PIPERAZIN-1-IL)-FENIL]-PIRAZOLO[1,5-A]PIRIMIDIN-7-IL-AMINA, ENTRE OTROS. SE REFIERE A UNA COMPOSICION Y UN PROCESO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE QUINASA DE DIFERENTES GRADOS DE ESPECIFICIDAD, POR LO QUE SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TALES COMO TUMOR BENIGNO O MALIGNOREFERS TO COMPOUNDS DERIVED FROM PYRAZOLO [1,5-a] PYRIMIDIN-7-IL-AMINE OF FORMULA (I), WHERE R1 IS H, HALOGEN OR LOWER ALKYL; R2 IS H, ARYL, HETEROARYL, LOWER ALKYL, CYCLOALKYL, BENZYL, BENZOTHENYL, INDOLYL, AMONG OTHERS, OPTIONALLY SUBSTITUTED; R3 IS H, LOWER RENT, OPTIONALLY REPLACED; A IS H, HALOGEN, BENZOTHENYL, PYRIDYL, PHENYL, PIPERAZINYL, AMONG OTHERS, OPTIONALLY SUBSTITUTED. PREFERRED COMPOUNDS ARE: 3- {7-AMINO-3- [4- (4-METHYL-PIPERAZIN-1-IL) -PHENYL] -PIRAZOLO- [1,5-A] -PIPRIMIDIN-6-IL} -PHENOL, 6- (3-BENZYLOXY-PHENYL) -3- [4- (4-METHYL-PIPERAZIN-1-IL) -PHENYL] -PYRAZOLO [1,5-A] PYRIMIDIN-7-IL) -PHENOL, 6- ( 3-METHOXY-PHENYL) -4- [4- (4-METHYL-PIPERAZIN-1-IL) -PHENYL] -PIRAZOLO [1,5-A] PYRIMIDIN-7-IL-AMINE, AMONG OTHERS. IT REFERS TO A COMPOSITION AND A PREPARATION PROCESS. THESE COMPOUNDS ARE INHIBITORS OF KINASE OF DIFFERENT DEGREES OF SPECIFICITY, SO THEY ARE USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS BENIGN OR MALIGNANT TUMOR
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53822004P | 2004-01-22 | 2004-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20051089A1 true PE20051089A1 (en) | 2006-01-25 |
Family
ID=34807167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005000080A PE20051089A1 (en) | 2004-01-22 | 2005-01-20 | PYRAZOLE [1,5-A] PYRIMIDIN-7-IL-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1708710A1 (en) |
JP (1) | JP2007519662A (en) |
KR (1) | KR20070009546A (en) |
CN (1) | CN1909908A (en) |
AR (1) | AR049769A1 (en) |
AU (1) | AU2005205915B2 (en) |
BR (1) | BRPI0507071A (en) |
CA (1) | CA2552885A1 (en) |
EC (1) | ECSP066718A (en) |
IL (1) | IL176737A0 (en) |
MA (1) | MA28400B1 (en) |
NO (1) | NO20063758L (en) |
PE (1) | PE20051089A1 (en) |
RU (1) | RU2006130003A (en) |
TN (1) | TNSN06226A1 (en) |
TW (1) | TW200528103A (en) |
WO (1) | WO2005070431A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
WO2007041712A1 (en) | 2005-10-06 | 2007-04-12 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
JP5152922B2 (en) * | 2005-10-06 | 2013-02-27 | メルク・シャープ・アンド・ドーム・コーポレーション | Use of pyrazolo [1,5-A] pyrimidine derivatives to inhibit protein kinases and methods for inhibiting protein kinases |
DK1973545T3 (en) | 2005-12-23 | 2013-02-25 | Ariad Pharma Inc | Bicyclic heteroaryl compounds |
RU2008139560A (en) * | 2006-03-08 | 2010-04-20 | Новартис АГ (CH) | APPLICATION OF PYRAZOLO [1,5a] PYRIMIDIN-7-ILAMINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISORDERS |
WO2007109183A2 (en) * | 2006-03-20 | 2007-09-27 | Novartis Ag | Mutations and polymorphisms of fms-related tyrosine kinase 1 |
GB0606804D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic Compounds |
GB0606805D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
US20100029636A1 (en) * | 2006-09-28 | 2010-02-04 | Peter Buehlmayer | Lck inhibitors |
US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
EP1918291A1 (en) * | 2006-10-30 | 2008-05-07 | Novartis AG | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators |
CA2689667A1 (en) * | 2007-06-07 | 2008-12-18 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
WO2010118207A1 (en) | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
WO2011041152A1 (en) | 2009-09-30 | 2011-04-07 | Schering Corporation | Novel compounds that are erk inhibitors |
UY33227A (en) * | 2010-02-19 | 2011-09-30 | Novartis Ag | PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6 |
RU2594742C2 (en) | 2010-05-20 | 2016-08-20 | Эррэй Биофарма Инк. | Macrocyclic compounds as trk kinase inhibitors |
EP2604606B1 (en) * | 2010-08-09 | 2014-10-08 | Pharmadesign, Inc. | Inhibitor of casein kinase 1delta and casein kinase 1epsilon |
WO2012023143A1 (en) | 2010-08-19 | 2012-02-23 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
KR101404151B1 (en) * | 2011-11-25 | 2014-06-05 | 가톨릭대학교 산학협력단 | Composition for preventing and treating ocular diseases |
CN105906630B (en) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | Two substitutional amine-group compounds of N- (1H- pyrazoles -5- bases) pyrimido pyrazoles -4,6- as FGFR inhibitor |
MX2018000577A (en) | 2015-07-16 | 2018-09-05 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors. |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
CN106588893A (en) * | 2016-12-01 | 2017-04-26 | 北京万全德众医药生物技术有限公司 | Preparation of vilazodone double oxide |
JP6888101B2 (en) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolo [1,5-a] pyrazine compounds as RET kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
CN111615514B (en) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors |
JP7060694B2 (en) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrolo [2,3-D] pyrimidine compounds as RET kinase inhibitors |
CN111630054B (en) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors |
US10988477B2 (en) * | 2018-01-29 | 2021-04-27 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
JP2022500383A (en) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Condensed heterocyclic compound as a RET kinase inhibitor |
CN109836428A (en) * | 2019-02-27 | 2019-06-04 | 华东师范大学 | Pyrazoles [4,3-d] pyrimidine derivatives and purposes with immunosuppressive activity |
EP3996736A4 (en) * | 2019-07-10 | 2023-05-24 | Musc Foundation for Research Development | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury |
CR20220308A (en) | 2019-11-25 | 2022-08-04 | Amgen Inc | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
TW202337433A (en) * | 2022-02-08 | 2023-10-01 | 美商德洛斯股份有限公司 | Compositions and methods for use in the treatment of cancer and other indications |
CN114751910B (en) * | 2022-05-17 | 2023-02-24 | 重庆文理学院 | Compound capable of inducing cell megalophage death and preparation method and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3130633A1 (en) * | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-AMINO-AZOLO (1,5-A) PYRIMIDINE AND FUNGICIDES CONTAINING THEM |
WO1992018504A1 (en) * | 1991-04-22 | 1992-10-29 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME |
JP3163413B2 (en) * | 1994-06-21 | 2001-05-08 | 株式会社大塚製薬工場 | Painkillers |
PT714898E (en) * | 1994-06-21 | 2002-04-29 | Otsuka Pharma Co Ltd | PYRAZOLONE-1,5-A | PYRIMIDINE DERIVATIVES |
WO1998010590A1 (en) * | 1996-09-02 | 1998-03-12 | Sony Corporation | Device and method for transmitting video signal |
EP1545533A1 (en) * | 2002-09-04 | 2005-06-29 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
EP1534710B1 (en) * | 2002-09-04 | 2007-10-24 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
-
2005
- 2005-01-20 PE PE2005000080A patent/PE20051089A1/en not_active Application Discontinuation
- 2005-01-20 AR ARP050100208A patent/AR049769A1/en unknown
- 2005-01-21 CN CNA2005800030379A patent/CN1909908A/en active Pending
- 2005-01-21 EP EP05706961A patent/EP1708710A1/en not_active Withdrawn
- 2005-01-21 KR KR1020067014683A patent/KR20070009546A/en not_active Application Discontinuation
- 2005-01-21 RU RU2006130003/15A patent/RU2006130003A/en not_active Application Discontinuation
- 2005-01-21 WO PCT/EP2005/000602 patent/WO2005070431A1/en active Application Filing
- 2005-01-21 JP JP2006550056A patent/JP2007519662A/en active Pending
- 2005-01-21 AU AU2005205915A patent/AU2005205915B2/en not_active Ceased
- 2005-01-21 CA CA002552885A patent/CA2552885A1/en not_active Abandoned
- 2005-01-21 TW TW094101852A patent/TW200528103A/en unknown
- 2005-01-21 BR BRPI0507071-6A patent/BRPI0507071A/en not_active IP Right Cessation
-
2006
- 2006-07-06 IL IL176737A patent/IL176737A0/en unknown
- 2006-07-10 MA MA29182A patent/MA28400B1/en unknown
- 2006-07-21 EC EC2006006718A patent/ECSP066718A/en unknown
- 2006-07-21 TN TNP2006000226A patent/TNSN06226A1/en unknown
- 2006-08-22 NO NO20063758A patent/NO20063758L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2007519662A (en) | 2007-07-19 |
ECSP066718A (en) | 2006-10-31 |
CN1909908A (en) | 2007-02-07 |
NO20063758L (en) | 2006-10-23 |
IL176737A0 (en) | 2006-10-31 |
RU2006130003A (en) | 2008-04-10 |
AU2005205915A1 (en) | 2005-08-04 |
CA2552885A1 (en) | 2005-08-04 |
WO2005070431A1 (en) | 2005-08-04 |
AU2005205915B2 (en) | 2009-05-21 |
TW200528103A (en) | 2005-09-01 |
BRPI0507071A (en) | 2007-06-19 |
KR20070009546A (en) | 2007-01-18 |
TNSN06226A1 (en) | 2007-12-03 |
MA28400B1 (en) | 2007-01-02 |
AR049769A1 (en) | 2006-09-06 |
EP1708710A1 (en) | 2006-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20051089A1 (en) | PYRAZOLE [1,5-A] PYRIMIDIN-7-IL-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | |
US9309253B2 (en) | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | |
JP4147184B2 (en) | 4-Amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives | |
Rudolph et al. | Chemically diverse group I p21-activated kinase (PAK) inhibitors impart acute cardiovascular toxicity with a narrow therapeutic window | |
JP5992054B2 (en) | Pyrazolopyrrolidine compound | |
FI112867B (en) | 4-Aminopyrrolo [2,3-d] pyrimidine derivatives and their use | |
JP6505023B2 (en) | Azabenzimidazole compounds as inhibitors of PDE4 isozymes for treating CNS and other disorders | |
AU2018200271A1 (en) | Compounds | |
JP6713982B2 (en) | Pyrazolopyrimidine compounds | |
Song et al. | Discovery of novel 2, 4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases | |
NZ597647A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
PE20091849A1 (en) | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | |
KR102061952B1 (en) | Imidazopyridazine compounds | |
PE20091468A1 (en) | DERIVATIVES OF 3-METHYL-IMIDAZINE- [1,2-b] -PYRIDAZINE | |
NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
DE602004011199D1 (en) | 5-PHENYLTHIAZOL DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | |
PE20081226A1 (en) | COMPOUNDS FOR THE MODULATION OF THE ACTIVITY OF THE C-FMS AND / OR THE C-KIT | |
TW200614990A (en) | Methods for preparing indazole compounds | |
EA202091475A1 (en) | 5- (2- (2,5-DIFLUOROPHENYL) PYRROLIDIN-1-YL) -3- (1H-PYRAZOL-1-YL) PYRAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS AS TRK KINASE INHIBITORS FOR TREATMENT CANCER | |
PE20191236A1 (en) | PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE OF THEM | |
AU2018328768A1 (en) | Inhibitors of WDR5 protein-protein binding | |
EP2920178A1 (en) | Novel heterocyclic derivatives as modulators of kinase activity | |
CA2925743C (en) | Novel bicyclic pyridinones as gamma-secretase modulators | |
CN1860121A (en) | Substituted imidazopyrimidines for the prevention and treatment of cancer | |
AU2014351413B2 (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |